Search / Trial NCT00001208

Botulinum Toxin for the Treatment of Involuntary Movement Disorders

Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Nov 3, 1999

Trial Information

Current as of December 26, 2024

Recruiting

Keywords

Botulinum Toxin Btw Natural History

ClinConnect Summary

This clinical trial is studying the use of botulinum toxin, a substance that can help treat involuntary movement disorders, which are conditions that cause unwanted movements in the body. The researchers want to see how effective this treatment is for various disorders, including problems like dystonia (where muscles contract uncontrollably), tremors, and spasmodic dysphonia (voice issues). They are also exploring the possibility of using a different type of botulinum toxin for patients who don't respond to the standard treatment.

To participate in the trial, individuals must be at least 2 years old and have a movement disorder that a doctor thinks could be treated with botulinum toxin. However, pregnant or breastfeeding women cannot take part, and certain medical conditions will exclude some participants. Those who join can expect to receive treatment and be monitored closely to see how well it works. The goal of this study is to improve treatment techniques and gain a better understanding of how botulinum toxin can help with these challenging conditions.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • 1. Patients 2 years and older, will be eligible for participation if they have a disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
  • 2. Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia.
  • EXCLUSION CRITERIA:
  • 1. Women who are planning on becoming pregnant, are pregnant or breastfeeding, for the duration of the condition.
  • 2. Subjects who require treatment with an aminoglycoside antibiotic, until treatment is complete.
  • 3. For laryngeal injections, subjects must have a paradoxical vocal fold movement with intermittent stridor due to either gastroesophageal reflux or emotional disorders

Trial Officials

Debra J Ehrlich, M.D.

Principal Investigator

National Institute of Neurological Disorders and Stroke (NINDS)

About National Institute Of Neurological Disorders And Stroke (Ninds)

The National Institute of Neurological Disorders and Stroke (NINDS) is a leading component of the National Institutes of Health (NIH), dedicated to advancing our understanding of the brain and nervous system through innovative research. NINDS sponsors and conducts clinical trials aimed at developing effective treatments and improving patient outcomes for a wide range of neurological disorders, including stroke, epilepsy, multiple sclerosis, and neurodegenerative diseases. By fostering collaboration among researchers, healthcare providers, and patient communities, NINDS plays a pivotal role in transforming scientific discoveries into clinical applications, ultimately enhancing the quality of life for individuals affected by neurological conditions.

Locations

Bethesda, Maryland, United States

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials